Vivacelle Bio Inc.

06/01/2024

Our company's, Vivacelle Bio's President and Chief Innovation Officer to Present Data Highlighting the Company's Late-Stage Clinical Programs at the BIO International Convention 2024 June 3 and 4th in San Diego.

/PRNewswire/ -- Vivacelle Bio, a late-stage biopharma company developing life-saving treatments for shock and trauma, today announced that Cuthbert Simpkins...

02/22/2023

https://www.openpr.com/.../hypovolemic-shock-market-to... Hypovolemic Shock Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies - Pharmazz, Perfusion Medical, Vivacelle Bio (https://vivacellebio.com/)
The Hypovolemic Shock market is expected to surge due to the disease s increasing prevalence and awareness during the forecast period Furthermore launching various multiple stage Hypovolemic Shock pipeline products will significantly revolutionize the Hypovolemic Shock market dynamics DelveInsight s ...
www.openpr.com

02/09/2023

https://www.businesswire.com/news/home/20230209005014/en/Vivacelle-Bio%E2%80%99s-VBI-S-Phase-IIa-Clinical-Trial-Meets-Primary-and-Secondary-Endpoints-for-Treating-Hypovolemia-in-Septic-Shock-Patients We are elated to announce the successful completion and the results of our Phase IIa Trial to treat Hypovolemia in Septic Shock patients. We achieved a 100% success response rate in meeting our primary endpoint & also met our secondary endpoint. Thanks to the herculean team effort at our company, Vivacelle Bio (VivacelleBio.Com) and our advisers at FDAMAP for bringing this to fruition.

Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic shock an

10/20/2022

https://www.businesswire.com/news/home/20221020005031/en/Vivacelle-Bio-Announces-Early-Results-of-its-Phase-IIa-Clinical-Trial-of-VBI-S-for-Improving-Hypovolemia-Due-to-Sepsis. We are elated to announce the early-mid stage results of our Phase IIa Trial to treat Hypovolemia due to Septic Shock. Thanks to the herculean team effort at our company, Vivacelle Bio and our advisers at FDAMap, a Washington, DC-based FDA Regulatory Advisory Firm.

Vivacelle Bio, Inc., a privately held company focused on the development of improved treatments for septic shock, today announced early results from i

10/08/2022

Septic Shock Market is Expected to Expand at a Healthy Growth Rate by (2022-2032), States DelveInsight | Key Companies – Adrenomed AG, Vivacelle Bio, Inotrem. Our company, Vivacelle Bio, is mentioned as one of the top three key companies within the niche indication of Septic Shock and Septic Shock Therapies and Key Companies. Read more: https://www.digitaljournal.com/pr/septic-shock-market-is-expected-to-expand-at-a-healthy-growth-rate-by-2022-2032-states-delveinsight-key-companies-adrenomed-ag-vivacelle-bio-inotrem

12/08/2021

Vivacelle Bio Awarded an NIH Grant
Vivacelle Bio has been awarded a $251,883.00 NIH Grant through its Small Business Innovative Research (SBIR) to develop a novel resuscitation fluid based on nano-colloid technology capable of potentially treating the hypotension and hypovolemia of refractory septic shock. Currently, there is no highly effective treatment for the hypotension and hypovolemia of late septic shock. To date, Vivacelle Bio has been awarded $5.3 million (USD) dollars from the Department of Defense issued on behalf of the Naval Medical Research Center (NMRC) under Medical Technology Enterprise Consortium (MTEC) and the foregoing $251,883.00 NIH Grant. shock medicine blood pressure blood volume.

06/30/2021

Link between sepsis, multiple organ failure and some artificial sweeteners. New Research Uncovers Dangers of [some] Artificial Sweeteners – Potentially Leading to Serious Health Issues. Study is the first to show that some of the sweeteners most commonly found in food and drink — saccharin, sucralose and aspartame — can make normal and ‘healthy’ gut bacteria become pathogenic. These pathogenic changes include greater formation of biofilms and increased adhesion and invasion of bacteria into human gut cells.“ These changes could lead to our own gut bacteria invading and causing damage to our intestine, which can be linked to infection, sepsis and multiple-organ failure. https://scitechdaily.com/new-research-uncovers-potential-dangers-of-artificial-sweeteners-can-cause-gut-bacteria-to-invade-the-intestine/?fbclid=IwAR0k8vtPylAXwzQGA2qVb148q4ayRAU5ZrsbNUul97MHBay2045cccJ6HzQ

Sweeteners could cause gut bacteria to invade the intestine. New research has discovered that common artificial sweeteners can cause previously healthy gut bacteria to become diseased and invade the gut wall, potentially leading to serious health issues. The study, published in the International

06/24/2021

Vivacelle Bio Nominated as a Top Biotechnology Company in Illinois. https://beststartup.us/?p=6700.

This article showcases our top picks for the best Illinois based Biotechnology companies. These startups and companies are taking a variety of approaches to innovating the Biotechnology industry, but are all exceptional companies well worth a follow. We tried to pick companies across the size spe

05/31/2021

Harvard-trained trauma surgeon, Dr. Cuthbert Simpkins, MD, Vivacelle Bio's Co-Founder, Chief Innovation Officer and President speaks to Northeast Indiana Innovation Center.

Dr. Cuthbert Simpkins, MD, FACS, is an experienced trauma surgeon who has been in practice for 40 years. He has successfully operated on patients with gunshot wounds to the heart and other vital organs. However, too many died later of septic shock due to infection. He grew increasingly frustrated with treatment options for these types of patients. In 2013, he brought a team together to work on this problem.

Now, as President and Chief Innovation Officer, Vivacelle Bio, Inc., he developed a new class of fluids to sustain life after massive blood loss or bloodstream infection.

During a recent fireside chat hosted by The NIIC Connected Health Lab, Dr. Simpkins spoke with Michael Fritsch, NIIC Senior Entrepreneur in Residence, about the process of biomedical discovery, development, and commercialization. Dr. Simpkins has been a part of the entrepreneurial community at The NIIC since 2016.

Read more: https://theniic.org/insights/trauma-surgeons-quest-for-patient-care-may-lead-to-innovation-in-septic-shock-treatment/



FUSE NEI Women's Entrepreneurial Opportunity Center

05/06/2021

Vivacelle Bio prominently featured in Hypovolemic Shock Market: Market Analysis, Leading Companies, Emerging Drugs, Epidemiology Forecast and Competitive Analysis by DevelInsight.
https://www.bignewsnetwork.com/news/269270023/hypovolemic-shock-market-market-analysis-leading-companies-emerging-drugs-epidemiology-forecast-and-competitive-analysis-by-delveinsight

Hypovolemic Shock Market Market Analysis Leading Companies Emerging Drugs Epidemiology Forecast and Competitive Analysis by DelveInsight

04/06/2021

Major Players in Hypovolemia
There are approx. 10+ key companies which are developing the therapies for Hypovolemia. The companies which have their Hypovolemia drug candidates in the most advanced stage, i.e. phase II include, Vivacelle Bio. https://www.marketresearch.com/.../Hypovolemia-Pipeline.../
DelveInsight’s, “Hypovolemia – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Hypovole… See More

04/03/2021

Use of phospholipid nanoparticles to treat hypovolemia due to septic shock.

Open Clinical Trial for the Evaluation of Novel Phospholipid Nanoparticles for the Treatment of Septic Shock Vivacelle Bio was recently cleared by the FDA to proceed with its Phase IIa clinical trial for evaluation of the safety and efficacy of VBI-S, an intravenously injected cardiovascular support...